For instance, drugs targeting activating mutations in the epidermal growth factor receptor (EGFR), such as gefitinib, have shown significant efficacy in patients with non-small cell lung cancer, particularly among those with radon-associated tumors harboring these alterations [43]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.